Do not vaccinate children against COVID-19 until Phase 3 trials are complete

Do not vaccinate children against COVID-19 until Phase 3 trials are complete – Is the Title to the petition created by Dr. Ros Jones and submitted to the UK Government and Parliament. The petition must collect 100,000 signatures and has a deadline of November 18, 2021.

You can sign the petition here: Do not vaccinate children against COVID-19 until Phase 3 trials are complete – Petitions (parliament.uk)

In the petition Dr. Ros Jones writes:

Do not vaccinate children against COVID-19 until Phase 3 trials are complete. Risk vs benefit calculation does not support giving COVID-19 vaccines, which use novel technologies and are still in Phase 3 trials, to healthy children. Any rollout should not start until trials are complete and all findings are published and peer-reviewed on long-term safety data.

Healthy children are at low risk from COVID-19. Do not vaccinate children

Healthy children are at low risk from COVID-19 yet face known and unknown risks from COVID-19 vaccines. Rare, but serious, adverse events and deaths are being reported to monitoring systems around the world. Official guidance is updated as the side effects become more apparent.

Giving COVID-19 vaccines to healthy children to protect adults is unethical and unjustifiable. The Government has an ethical duty to act with caution and proportionality.

The UK government’s response came promptly

The Government will continue to evaluate evidence and assess expert opinion before making a decision on routinely vaccinating children under 18 years old.

No decision has been made by the Government regarding the routine inclusion of children under 18 years within the COVID-19 vaccination program at a population level.

The Government will be guided by the advice of the UK’s independent medicines regulator, the Medicines and Healthcare products Regulatory Agency (MHRA), whose role is to ensure medicines, devices, and vaccines work effectively and are safe for use.

MHRA has now authorized the use of the Pfizer/ BioNTech vaccine in children aged 12-15. This follows a rigorous review of the safety, quality, and effectiveness of the vaccine in this age group by the MHRA and the Government’s independent advisory body, the Commission on Human Medicines (CHM).

Over 2,000 children aged 12-15 years were studied as part of the randomized, placebo-controlled clinical trials. There were no cases of COVID-19 from 7 days after the second dose in the vaccinated group, compared with 16 cases in the placebo group. In addition, data on neutralizing antibodies showed the vaccine working at the same level as seen in adults aged 16-25 years.

No new side effects were identified and the safety data in children was comparable with that seen in young adults. As in young adults, the majority of adverse events were mild to moderate and relating to reactogenicities, such as a sore arm or tiredness.

Any vaccine must first go through the usual rigorous testing

Any vaccine must first go through the usual rigorous testing and development process and meet strict standards of safety, quality and effectiveness before it can be deployed. There are extensive checks and balances at every stage of the development of a vaccine. The data looked at includes all the results from laboratory studies, clinical trials, manufacturing and quality controls, and testing of the product. The public should be very confident that all tests are completed to the very highest standards.

For all vaccines authorized for supply in the UK, including COVID-19 vaccines, each candidate is assessed by teams of scientists and clinicians on a case-by-case basis and is only authorized once it has met robust standards of effectiveness, safety, and quality set by MHRA.

Once a vaccine is approved for use in the UK, the Joint Committee on Vaccination and Immunisation (JCVI), an independent body made up of scientific and clinical experts, will provide advice to the Government on which safe, effective vaccines to use, and advise on prioritization at a population level.

The committee’s membership is made up of public health and scientific experts who have considered and continue to consider the impact of COVID-19 and population prioritization as new data emerges.

Now that the Pfizer/BioNTech vaccine has been authorized for use in children aged 12-15 in the UK, we will be guided by the advice of experts, including the JCVI, on any potential deployment of COVID-19 vaccination in children under the age of 18.

No decisions have been made by the Government on the routine COVID-19 vaccination of children.

In line with the advice of the JCVI for Phase One of the vaccination program, children/young adults aged 16-18 could be offered a vaccine if they have an underlying condition that puts them at increased risk from COVID-19. However, the JCVI currently advises that children under 16 years of age, even if they are clinically extremely vulnerable (CEV), are at low risk of serious morbidity and mortality and given the absence of safety and efficacy data on COVID-19 vaccines, are not currently recommended for routine COVID-19 vaccination.

Following infection, almost all children will also have an asymptomatic infection or mild disease. Therefore, only children under 16 who are at very high risk of exposure and serious outcomes, such as those with severe neuro-disabilities that require residential care, may be considered for a COVID-19 vaccination. This is given the very high risk of exposure to infection and outbreaks in residential settings.

Decisions to vaccinate such children should be made on a case-by-case basis, with consultation taking place between clinicians, parents/carers, and children.

Dr. Simon Clarke, Associate Professor in Cellular Microbiology at the University of Reading, said:

‘We should remember that vaccinating young people to protect older or more vulnerable people is already common, including with newly-developed vaccines. A new flu vaccine is created every year, and once it is tested for safety and efficacy, as has happened with covid jabs, it is rolled out to the general population.

In the UK children get the new flu vaccine every year from age four, mainly to prevent them from catching and spreading the flu to older adults, who are most vulnerable to dying from the flu.

Vaccines always have side effects and risks, but the scientific evidence shows the risk to individuals and wider society of not being vaccinated is a greater risk. Yes, there are risks of side effects from the jab for children. ”

Do not vaccinate children to protect adults? Have our children become the guinea pigs of the world? Shame!

The MHRA updated its authorization guidance in relation to the currently approved vaccines in February to allow this approach.

The JCVI continues to look at the emerging evidence on COVID-19 and will offer further advice to the Government if and when evidence is found that routinely vaccinating children under 18 years old would further reduce overall mortality, morbidity, and hospitalization which is the overarching objective of the COVID-19 vaccination program.

Congratulations to the UK Government for the right decisions!

You can sign the petition here: Do not vaccinate children against COVID-19 until Phase 3 trials are complete – Petitions (parliament.uk)

CONCLUSION: example should be followed by all countries. We also wonder why children should be vaccinated if they are not affected by COVID and there are no deaths among children.

Sarcastic Note: Almost the entire globe was vaccinated, and yet no change, to return to normal. Then where is the problem? Go and vaccinated, the boosters will be almost monthly until you become addicted.